The utility of copeptin in the emergency department as a predictor of adverse outcomes in non-ST-elevation acute coronary syndrome: The COPED-PAO study

Emergency Medicine Journal

Volumn 31, Issue 4, 2014, Pages 286-291

  Sánchez, Miquel ^a   Llorens, Pere ^b   Herrero, Pablo ^c   Martín Sanchez, F Javier ^d   Piñera, Pascual ^e   Miró, Òscar ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

COPEPTIN; TROPONIN I; TROPONIN T; BIOLOGICAL MARKER; GLYCOPEPTIDE; TROPONIN;

ACUTE HEART FAILURE; ADVERSE OUTCOME; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CHRONIC LUNG DISEASE; COHORT ANALYSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DYSLIPIDEMIA; ELECTROCARDIOGRAPHY MONITORING; EMERGENCY WARD; FAMILY HISTORY; FEMALE; HEART CATHETERIZATION; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; ISCHEMIC CARDIOMYOPATHY; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OBSERVATIONAL STUDY; PATIENT ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SMOKING; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; UREA NITROGEN BLOOD LEVEL; ACUTE CORONARY SYNDROME; BLOOD; CLINICAL TRIAL; EMERGENCY HEALTH SERVICE; LONGITUDINAL STUDY; MIDDLE AGED; MULTICENTER STUDY; RECEIVER OPERATING CHARACTERISTIC; SPAIN; VERY ELDERLY;

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; EMERGENCY SERVICE, HOSPITAL; FEMALE; GLYCOPEPTIDES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; ROC CURVE; SPAIN; TROPONIN;

EID: 84896084537     PISSN: 14720205     EISSN: 14720213     Source Type: Journal    
DOI: 10.1136/emermed-2012-201996     Document Type: Article

References (25)

1. Hamm CW, Bassand JP, Agewall S, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force for the management of acute coronary syndrome (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999-3054.
2. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. J Am Med Assoc 2000;284:835-42. (Pubitemid 30643610)
3. Fox KA, Dabbous OH, Goldberg RJ, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ 2006;333:1091.
4. Morrow DA, Sabatine MS, Brennan ML, et al. Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J 2008;29:1096-102. (Pubitemid 351844877)
5. Tousoulis D, Kampoli AM, Stefanadi E, et al. New biochemical markers in acute coronary syndrome. Curr Med Chem 2008;15:1288-96. (Pubitemid 351997798)
6. Brügger-Andersen T, Aarsetoy H, Grundt H, et al. The long-term prognostic value of multiple biomarkers following a myocardial infarction. Thromb Res 2008:123:60 -6.
7. Struck J, Morgenthaler NG, Bergmann A. Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients. Peptides 2005;26:2500-4. (Pubitemid 41676723)
8. Reichlin T, Hochholzer W, Stelzig C, et al. Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol 2009;54:60-8.
9. Epelde F. Ischemic heart disease: the role of emergency health services in improving survival. Emergencias 2011;23:426- 8.
10. Carbajosa Dalmau J, Llorens P, Diéguez Zaragoza S, et al. Sex-related differences in emergency department management of acute coronary syndrome with ST elevation. Emergencias 2011;23:87-92.
11. Keller T, Tzikas S, Zeller T, et al. Copeptin improves early diagnosis of acute myocardial infarction. J Am Coll Cardiol 2010;55:2096 -106.
12. Khan SQ, Dhillon OS, O'Brien RJ, et al. C-terminal porvasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction. Leicester Acute Myocardial Infarction Peptide (LAMP) Study. Circulation 2007;115:2103-10. (Pubitemid 46659061)
13. Kelly D, Squire IB, Khan SQ, et al. C-terminal porvasopressin (copeptin) is associated with left ventricular dysfunction, remodeling, and clinical haert failure in survivors of myocardial infarction. J Card Fail 2008;14:739-45.
14. Voors AA, von Haehling S, Anker SD, et al. C-terminal porvasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur Heart J 2009;30:1187-94.
15. Schnabet RB, Schulz A, Messow CM, et al. Multiple marker approach to risk stratification in patients with stable coronary artery disease. Eur Heart J 2010;31:3024-31.
16. Mellbin LG, Rydén L, Brismar K, et al. Copeptin, IGFBP-1, and cardiovascular prognosis in patients with type 2 diabetes and acute myocardial infarction: a report from the DIGAMI-2 trial. Diabetes Care 2010;33:1604-6.
17. Narayan H, Dhillon OS, Quinn PA, et al. C-terminal provasopressin (copeptin) as a prognostic marker after acute non-ST elevation myocardial infarction: Leicester Acute Myocardial Infarction Peptide II (LAMP II) study. Clin Sci 2011;121:79-89.
18. Von Haehling S, Papassotiriou J, Morgenthaler NG, et al. Copeptin as a prognostic factor for major adverse cardiovascular events in patients with coronary artery disease. Int J Cardiol 2012;162:27-32.
19. Fortuny E, Núñez Gil IJ, García-Rubira JC, et al. Clinical importance of early intensive medical treatment for improving prognosis in non-ST-elevation acute coronary syndrome. Emergencias 2011;23:461 -7.
20. Montiel Dacosta JA, Santaló Bel M, Balaguer Martínez JV, et al. Short-term prognostic factors in elderly patients treated in emergency departments for acute coronary syndrome with ST segment elevation. Emergencias 2011;23:355-60.
21. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: the Task Force for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes of the European Society of Cardiology. Eur Heart J 2007;28:1598-660. (Pubitemid 47227122)
22. Gibbons RJ, Balady GJ, Bricker JT, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation 2002;106:1883 -92.
23. Apple FS, Ler R, Murakami MM. Determination of 19 cardiac troponin I and T assay 99th percentile values from a common presumably healthy population. Clin Chem 2012;58:1574-81.
24. Sánchez M, Bauset JL, Cuervo R, et al. Management of non-ST-segment elevation acute coronary syndromes in emergency departments according to hospital size: cases from the Emergency Management of Acute Coronary Syndrome (MUSICA) registry. Emergencias 2011;23:447-54.
25. Hochholzer W, Morrow DA, Giugliano RP. Novel biomarkers in cardiovascular disease: update 2010. Am Heart J 2010;160:583-94.